Bruno Chalom Sayada

Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada

Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent.

ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA.

Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN.

Part of Bayer AG, ACT Gene SA is a French company that provides diagnostic laboratory services specializing in gene sequencing. The company is based in Paris, France. ACT Gene was acquired by Visible Genetics, Inc. on April 23, 1998 for $1.22 million.

Advanced Biological Laboratories SA develops information technology and health solutions for patient management and sequencing data analysis. Its products. Its products are marketed under the brands of TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, and HepatiC™. The company was founded by Chalom Bruno Sayada in 2000 and is headquartered in Luxembourg.

TrioBiotics Pharma AG manufactures pharmaceuticals for the treatment of psychiatric, cancer and infectious diseases. It offers anti-infectives for chronic and infectious disease markets. The company is headquartered in Zurich, Switzerland.

Probiox SA engages in the development and commercialization of solutions based on oxidative stress markers. The firm owns intellectual property related to the analysis and interpretation of oxidative stress parameters. It also provides turnkey solutions to companies for the evaluation of the antioxidant/anti-inflammatory properties of their products. The company's services include intellectual deliveries (literature reviews and scientific records for starting projects, registrations, claims, marketing support and scientific survey), clinical studies (assessment of oxidative stress in the context of existing studies or conducting turnkey studies) and In Vitro studies. Probiox was founded in 2001 and is headquartered in Liege, Belgium.